Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

Caliper's CDAS unit enters cancer research collaboration with Denver-based CHI

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life-sciences research, today announced that its Caliper Discovery Alliances and Services unit has formed a research collaboration with Denver-based Catholic Health Initiatives, one of the nation's largest health systems.

6 Apr 2011

Estrogen only hormone replacement not so risky after 50’s: Study

According to a new study hormone therapy may not be as risky for elder women as earlier thought. This comes from the Women's Health Initiative, a federally funded trial that tracked thousands of women taking hormones or placebo pills for years. The WHI looked at women who have had hysterectomies or have had their uterus removed and thus can take estrogen unaccompanied by another hormone, progestin. It found that a heightened risk of stroke from taking estrogen faded with time, while a reduced risk of breast cancer held steady.

5 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

Rsearchers define new step that controls programmed cell death in cancer cells

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death.

2 Apr 2011

Blocking TNF-related apoptosis-inducing ligand pathway partially reconstitutes HBV-specific T cells

A new study presented today at the International Liver Congress shows a novel pathway where activated natural killer (NK) cells expressing death ligands may excessively down-modulate the antiviral immune response in chronic HBV patients.

2 Apr 2011

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death. In contrast to other stress-induced genes, which dispense with the regular transcriptional entourage, p21Cip1 still requires SKIP, a transcription elongation factor that also helps with the editing of transcripts, to be expressed, found researchers at the Salk Institute for Biological Studies.

2 Apr 2011

PUMA-mediated intestinal apoptosis contributes to ulcerative colitis in humans, mice

Ulcerative colitis is an inflammatory bowel disease thought to be related to aberrant activation of the immune system in the intestine. Recent research has also suggested that regulated cell death of the intestinal epithelial cells is a contributing factor to the pathogenesis.

2 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Syndax to present entinostat data against cancer at AACR meeting

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.

1 Apr 2011

Researchers develop new drug for multiple cancer treatment

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.

30 Mar 2011

EpiCept enters agreement with institutional investor to purchase 7.1 million shares of common stock

EpiCept Corporation announced today that it has entered into a definitive agreement with an institutional investor for the purchase of approximately 7.1 million shares of its common stock at $0.65 per share, and five and one half year warrants to purchase up to approximately 5.3 million shares of common stock at an exercise price of $0.72 per share that are not exercisable for six months following the closing date of the offering.

29 Mar 2011

APC-300 drug significantly inhibits pancreatic cancer cell growth: Adamis

Adamis Pharmaceuticals Corporation announced today that in addition to its activity in prostate cancer, its drug APC-300 significantly inhibits the growth of pancreatic cancer cells.

25 Mar 2011

Researchers update 'Hallmarks of Cancer' seminal review

Renowned cancer researchers Robert Weinberg, a Founding Member of Whitehead Institute, and Douglas Hanahan, Director of the Swiss Institute for Experimental Cancer Research have updated their seminal review, "Hallmarks of Cancer," which has influenced the study of cancer and the development of therapeutics for more than a decade.

17 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

FDA holds Senesco's SNS01-T clinical study due to delay of supplier's DMF updation

Senesco Technologies, Inc., announced today that the U.S. Food and Drug Administration has informed the Company that its planned study in multiple myeloma is on hold until the Drug Master File of one of its suppliers is updated.

11 Mar 2011

Scientists develop new model for neurodegenerative disease

A team of scientists at the University of California, San Francisco has developed a new model for how inherited genes contribute to a common but untreatable and incurable neurodegenerative disease.

10 Mar 2011

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

10 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Apoptosis News and Research

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Caliper's CDAS unit enters cancer research collaboration with Denver-based CHI

Estrogen only hormone replacement not so risky after 50’s: Study

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Rsearchers define new step that controls programmed cell death in cancer cells

Blocking TNF-related apoptosis-inducing ligand pathway partially reconstitutes HBV-specific T cells

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

PUMA-mediated intestinal apoptosis contributes to ulcerative colitis in humans, mice

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Syndax to present entinostat data against cancer at AACR meeting

Researchers develop new drug for multiple cancer treatment

EpiCept enters agreement with institutional investor to purchase 7.1 million shares of common stock

APC-300 drug significantly inhibits pancreatic cancer cell growth: Adamis

Researchers update 'Hallmarks of Cancer' seminal review

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

FDA holds Senesco's SNS01-T clinical study due to delay of supplier's DMF updation

Scientists develop new model for neurodegenerative disease

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News